Bladder Cancer VL

The State of Immunotherapy in Bladder Cancer - Thomas Powles

Details
Thomas Powles discusses the current state of immunotherapy in the treatment of muscle-invasive bladder cancer (MIBC) specifically in the second-line after cisplatin-based chemotherapy with Chuck Ryan. He discusses the recent learnings that immunotherapy offers a long-term durable response in 10 - 20% of the cisplatin-eligible patient population who are biomarker positive. They discuss ongoing clin...

Bladder Cancer in Women: Improving Diagnosis and Treatment - Jean Hoffman-Censits

Details
Jean Hoffman-Censits joins Alicia Morgans and shares details on the Johns Hopkins women’s bladder cancer program. This program is created in recognition of the pathway that women frequently take in the diagnosis of their bladder cancer. We often see a delay in the diagnostic process of bladder cancer in women compared to men. This delay in diagnosis leads to what is thought to be stage migration....

Optimal Surgical Approaches in Cystectomy - Piyush Agarwal

Details
Piyush Agarwal reflects on a debate at the EAU 2019 where he debated Seth Lerner, MD who is a preeminent urologist in bladder cancer. Dr. Lerner was favoring open surgery and Dr. Agarwal was favoring robotic surgery for the purpose of the debate as he conveys the positioning of the arguments with Charles Ryan. If you look at the robotic literature in urologic cancers, there is no evidence of any o...

Improving Outcomes in Bladder Cancer - Arnulf Stenzl

Details
Arnulf Stenzl is the co-facilitator of the case-based specialty session. Here he discusses improving outcomes in non-muscle invasive bladder cancer with the en bloc resection for cancers that are smaller than one centimeter which is consistent with the EAU guidelines. Dr. Stenzl has been performing en bloc resections for tumors up to 3 centimeters which provides more information on staging. He als...

The Role of the Surgeon in the Management of Metastatic Bladder Cancer - Brant Inman

Details
Brant Inman discusses the role of the surgeon in the management of metastatic bladder cancer. Oftentimes surgical management is overlooked in favor of systemic therapies, including chemotherapy and immunotherapy. However, in certain cases, a surgical approach may provide a higher cure rate. Dr. Inman and Dr. Kamat discuss appropriate patient selection and scenarios for surgery and the role of neoa...

Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer - Stephen B Williams

Details
Stephen Williams and his team explored the question, what is the association of patient survival and intensity of treatment with total Medicare costs that are associated with radical cystectomy vs trimodal therapy for older adults with localized muscle-invasive bladder cancer in a time frame of longer than 180-days? He and Alicia Morgans discuss the study, its findings, and implications in patient...

Defining BCG-Unresponsive and The Pathway to Clinical Trials in Treating NMIBC - Ashish Kamat

Details
Ashish Kamat, MD discusses the focus of the International Bladder Cancer Group, discussing the pathway to developing the definition of BCG-unresponsive. Today the unified definition of BCG-unresponsive disease essentially denotes those patients for whom any more BCG is futile. This has opened the door to many ongoing clinical trials. The discussion moves to review these trials, including Nadofarag...

2019 BCG Shortage-Perspectives from Josh Meeks

Details
Josh Meeks and Alicia Morgans discuss the clinical treatment of high-risk NMIBC in a BCG rationed era. Biographies: Josh J. Meeks, MD, PhD, Assistant Professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, Chicago Illinois Alicia Morgans, MD, MPH , Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern...

Blue Light Cystoscopy with Cysview® in the Surveillance of Bladder Cancer - Sia Daneshmand

Details
Sia Daneshmand joins Ashish Kamat in a conversation on the phase III trial comparing blue light flexible cystoscopy with white light flexible cystoscopy for the detection of bladder cancer during surveillance. This study shows significant improvement of the detection of patients with recurrent bladder cancer and for the detection of carcinoma in situ, detecting lesions that are missed with white l...

The Importance of TURBT and the Benefits of Enhanced Cystoscopy - Sima P. Porten

Details
Sima Porten speaks about the importance of TURBT and the benefits of enhanced cystoscopy to the patient. She references the new AUA/SUO guidelines recommendation for enhanced cystoscopy and the benefit of Blue Light with Cysview®. Biography: Sima P. Porten, MD, MPH, Assistant Professor, Department of Urology, UCSF Medical Center Related Content: Efficacy and Safety of Blue Light Flexible Cystoscop...